This is a preclinical research collaboration with no financial terms or near-term catalysts. Monitor for any subsequent material agreements, equity financings, or clinical data releases. The stock's micro-cap status and low analyst coverage mean any positive news could cause outsized moves, but the lack of concrete financial commitment limits near-term trading relevance.
Price Chart
Executive Summary
Galmed Pharmaceuticals announced a collaboration with Tissue Dynamics to develop a human cardiac fibrosis organoid platform for Aramchol-based therapeutics. The press release contains no financial terms, no revenue, no clinical data, and no binding financial commitment — it is a preclinical research collaboration announcement with no quantifiable impact on the company's financial position.
Key Facts
- Galmed and Tissue Dynamics announced a collaboration to develop a human chronic cardiac fibrosis model using vascularized, sensor-embedded cardiac organoids.
- The platform will focus on chronic post-MI remodeling and HFpEF, linking lipid metabolism, SCD1 activity, fibrosis, and impaired tissue repair.
- No financial terms, milestones, or funding amounts were disclosed in the press release.
- No clinical data, regulatory filings, or revenue implications were reported.
- Galmed's market cap is approximately $4M, and the stock has 0% analyst bullish consensus.
Financial Impact
No financial terms disclosed — collaboration is preclinical with no stated milestones or payments.
Risk Factors
- No revenue or approved products — Galmed is a pre-revenue clinical-stage biopharma with a $4M market cap.
- The collaboration is preclinical; there is no guarantee of successful model development or therapeutic advancement.
- Galmed has a history of dilutive equity financings (Standby Equity Purchase Agreement, multiple shelf registrations) which could pressure the stock.
- Nasdaq listing maintenance risk given the micro-cap market capitalization.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001493152-26-021404 |
| Document: form6-k.htm | 0001493152-26-021404 |
| Document: 0001493152-26-021404-index-headers.html | 0001493152-26-021404 |
| Document: 0001493152-26-021404-index.html | 0001493152-26-021404 |
| Document: 0001493152-26-021404.txt | 0001493152-26-021404 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 6w ago | 6-K | $4.63 $3.63 | ▼ −21.71% | ▼ −21.37% | — |
Sep 4, 2026 7w ago | EFFECT | $3.88 $4.63 | ▼ −19.33% | ▼ −20.54% | — |
Sep 3, 2026 7w ago | 6-K | $3.88 $4.63 | ▲ +19.33% | ▲ +20.54% | — |
Sep 2, 2026 7w ago | 6-K | $3.92 $4.63 | ▲ +18.11% | ▲ +19.26% | — |
Aug 19, 2026 9w ago | 6-K | $4.77 $4.33 | ▼ −9.22% | ▼ −8.84% | — |
Aug 17, 2026 10w ago | 6-K | $0.5134 | awaiting T+5 | — | — |
Jul 28, 2026 12w ago | 6-K | $0.5340 $0.5754 | ▲ +7.75% | ▲ +3.64% | — |
Jul 16, 2026 14w ago | 6-K | $0.5501 $0.5530 | ▲ +0.53% | ▲ +2.20% | — |
Jun 22, 2026 18w ago | 6-K | $0.5641 $0.5709 | ▲ +1.21% | ▲ +1.66% | — |
Jun 8, 2026 20w ago | 6-K | $0.4693 $0.6160 | ▲ +31.26% | ▲ +29.15% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers